NCT06668493 - Low-grade UTUC Treated With Nadofaragene Firadenovec Administered to Renal Pelvis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 12, 2025

Primary Completion Date

November 30, 2029

Study Completion Date

November 30, 2029

Conditions

Low-grade Upper Tract Urothelial Carcinoma

Interventions

DRUG

Nadofaragene Firadenovec

Repeat dose trial to investigate the safety and efficacy of nadofaragene firadenovec instilled into the renal pelvis

Trial Locations (3)

RECRUITING

Memorial Sloan Kettering Cancer Center, New York

RECRUITING

University of Pennsylvania - Perelman Center for Advanced Medicine - Penn Urology, Philadelphia

RECRUITING

Indiana University, Indianapolis